Kurzporträt
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Transformative Cell and Exosome-based Therapeutics
100,0
%
| 3 | 100,0 % | 25 | 100,0 % | +886.81% |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 3 | 100,0 % | 25 | 100,0 % | +886.81% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 20.11.13 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 20.11.13 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.21 |
Karen Krasney
LAW | General Counsel | 71 | 01.01.12 |
General Counsel | 71 | 28.02.15 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 21.07.23 |
Earl Collier
BRD | Director/Board Member | 76 | 20.11.13 |
George Dunbar
BRD | Director/Board Member | 77 | 20.11.13 |
David Musket
BRD | Director/Board Member | 66 | 20.11.13 |
Frank Litvack
CHM | Chairman | 68 | 01.01.12 |
Karimah Es Sabar
BRD | Director/Board Member | 66 | 23.07.21 |
Linda Marbán
CEO | Chief Executive Officer | 60 | 20.11.13 |
Paul Auwaerter
BRD | Director/Board Member | 62 | 13.07.23 |
Michael Kelliher
BRD | Director/Board Member | 47 | 01.09.23 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 31 502 972 | 28 874 629 ( 91,66 %) | 0 | 91,66 % |
Unternehmenskontakt
Capricor Therapeutics, Inc.
10865 Road to the Cure Suite 150
92121, San Diego
+858 727 1755
http://www.capricor.comSektor
% 1. Jan. | Kap. | |
---|---|---|
-1.65% | 104 Mrd. | |
+6.75% | 97.47 Mrd. | |
+5.71% | 22.25 Mrd. | |
-12.60% | 21.68 Mrd. | |
-9.70% | 18.2 Mrd. | |
-39.98% | 17.02 Mrd. | |
-10.17% | 16.36 Mrd. | |
+6.12% | 14.39 Mrd. | |
+35.47% | 12.37 Mrd. |